SynOx Therapeutics Ltd

TANGENT met its primary and secondary endpoints with a high level of statistical significance vs. placebo at 6 months, including ORR by RECIST V1.1 and Tumor Volume Score (TVS), and clinically meaningful improvements in PROMIS-PF and other patient -releva

SynOx Therapeutics Announces Positive Topline Results from the Phase 3 TANGENT Study, Supporting Emactuzumab as a Differentiated, Next-generation Treatment for Patients with Tenosynovial Giant Cell Tumor (TGCT) TANGENT met its primary and secondary endpoi

Charles "Chip" Romp and Tom Heyman join SynOx's Board, bringing deep launch, lifecycle, and corporate development expertise as the company advances its next-generation therapy emactuzumab toward key regulatory and commercial milestones DUBLIN, IRELAND, OX

Top-Line Results from Study Evaluating Emactuzumab for Tenosynovial Giant Cell Tumours (TGCT) Expected in First Quarter of 2026 DUBLIN, IRELAND, OXFORD, UK, and PHILADELPHIA, PA - August 5, 2025 SynOx Therapeutics Limited ("SynOx"), a late-stage clinical

DUBLIN, IRELAND and OXFORD, UK, April 14, 2025 - SynOx Therapeutics Limited ("SynOx"), a late-stage clinical biopharmaceutical company developing of emactuzumab for Tenosynovial Giant Cell Tumours (TGCT), today announced that the United States Food and Dr

Newly Appointed Board Chair, Philip Astley-Sparke, Brings Transatlantic Late-Stage Development, Regulatory and Commercial Expertise Strengthened Leadership and Expanded U.S. Presence Positions SynOx for Regulatory Filings and Commercialization of Emactuzu

Additions of Elyse Seltzer, M.D., as CMO and Robert Francomano as CCO Strengthen Company's Presence in the U.S. Seasoned Team to Drive Forward Pivotal Phase 3 Trial of Emactuzumab in Patients Suffering from Tenosynovial Giant Cell Tumours (TGCT) DUBLIN, I